607 related articles for article (PubMed ID: 28056100)
1. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
[TBL] [Abstract][Full Text] [Related]
4. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
5. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
6. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
7. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Kalnin K; Chivukula S; Tibbitts T; Yan Y; Stegalkina S; Shen L; Cieszynski J; Costa V; Sabharwal R; Anderson SF; Christensen N; Jagu S; Roden RBS; Kleanthous H
Vaccine; 2017 Sep; 35(37):4942-4951. PubMed ID: 28778613
[TBL] [Abstract][Full Text] [Related]
9. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
[TBL] [Abstract][Full Text] [Related]
10. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
11. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.
Zacharia A; Harberts E; Valencia SM; Myers B; Sanders C; Jain A; Larson NR; Middaugh CR; Picking WD; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Ernst RK; Marshall JD
Vaccine; 2021 Jan; 39(2):292-302. PubMed ID: 33309485
[TBL] [Abstract][Full Text] [Related]
12. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
13. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
Ahmels M; Mariz FC; Braspenning-Wesch I; Stephan S; Huber B; Schmidt G; Cao R; Müller M; Kirnbauer R; Rösl F; Hasche D
Front Immunol; 2022; 13():1010790. PubMed ID: 36263027
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
Pineo CB; Hitzeroth II; Rybicki EP
Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
17. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
[TBL] [Abstract][Full Text] [Related]
18. Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.
Valencia SM; Zacharia A; Marin A; Matthews RL; Wu CK; Myers B; Sanders C; Difilippantonio S; Kirnbauer R; Roden RB; Pinto LA; Shoemaker RH; Andrianov AK; Marshall JD
Hum Vaccin Immunother; 2021 Aug; 17(8):2748-2761. PubMed ID: 33573433
[TBL] [Abstract][Full Text] [Related]
19. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
20. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
